Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M Cordes

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Journal for Immunotherapy of Cancer|March 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancerChennan Li, Ravi A Madan, Min-Jung Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2020
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary CancerHeather J Chalfin, Tiziano Pramparo, Amir Mortazavi, et al.
The Lancet. Oncology|July 10, 2020
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trialAndrea B Apolo, Rosa Nadal, Yusuke Tomita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2020
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary TumorsAndrea B Apolo, Rosa Nadal, Daniel M Girardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2024
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary TumorsAndrea B Apolo, Daniel M Girardi, Scot A Niglio, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Journal for Immunotherapy of Cancer|March 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancerChennan Li, Ravi A Madan, Min-Jung Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2020
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary CancerHeather J Chalfin, Tiziano Pramparo, Amir Mortazavi, et al.
The Lancet. Oncology|July 10, 2020
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trialAndrea B Apolo, Rosa Nadal, Yusuke Tomita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2020
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary TumorsAndrea B Apolo, Rosa Nadal, Daniel M Girardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2024
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary TumorsAndrea B Apolo, Daniel M Girardi, Scot A Niglio, et al.
Pageof 4